Literature DB >> 27448535

Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies.

Agata Bielecka-Dabrowa1, Agata Sakowicz2, Małgorzata Misztal3, Stephan von Haehling4, Ali Ahmed5, Tadeusz Pietrucha2, Jacek Rysz6, Maciej Banach7.   

Abstract

BACKGROUND/
OBJECTIVES: To evaluate whether biomarkers reflecting pathophysiological pathways and selected single nucleotide polymorphisms differ between patients (pts) with heart failure (HF).
METHODS: 110 pts with were involved, including HF pts with preserved ejection fraction (HFpEF, n=51) with hypertensive origin, HF pts with reduced ejection fraction (HFrEF) with ischemic aetiology (ICM) (n=32) and HFrEF with dilated cardiomyopathy (DCM) (n=27). We assessed selected HF biomarkers, echocardiographic examinations and functional polymorphisms selected from six candidate genes: CYP27B1, NOS3, IL-6, TGF beta, TNF alpha, and PPAR gamma.
RESULTS: Higher concentrations of TNF alpha were observed in pts with hypertensive HFpEF compared to pts with DCM (p=0.008). Pts with HFpEF had higher concentrations of TGF beta 1 compared to DCM and ICM (p=0.0001 and p=0.0003, respectively). For the NOS3 -786 C/T rs2070744 polymorphism in DCM there were significantly more CT heterozygotes than in ICM and HFpEF. In multivariate analysis TGF beta 1 (p=0.001) and syndecan 4 (p=0.001) were the only factors distinguishing HFrEF pts with DCM vs HFpEF and also TGF beta 1 (p=0.001) and syndecan 4 (p=0.023) were the only factors distinguishing HFrEF pts with ICM vs HFpEF pts.
CONCLUSIONS: Inflammation mediated through TNF alpha and TGF beta 1 may represent an important component of an inflammatory response that partially drives the pathophysiology of HFpEF. NOS3 -786 C/T rs2070744 polymorphism in DCM may serve as a marker for more rapid progression of heart failure. The only biomarkers independently distinguishing HFpEF and HFrEF are syndecan 4 and TGF beta 1.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Dilated cardiomyopathy; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction

Mesh:

Substances:

Year:  2016        PMID: 27448535     DOI: 10.1016/j.ijcard.2016.07.150

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  18 in total

Review 1.  Transforming growth factor-β in myocardial disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Nat Rev Cardiol       Date:  2022-01-04       Impact factor: 32.419

2.  Skeletal myopathy in a rat model of postmenopausal heart failure with preserved ejection fraction.

Authors:  Rachel C Kelley; Lauren Betancourt; Andrea M Noriega; Suzanne C Brinson; Nuria Curbelo-Bermudez; Dongwoo Hahn; Ravi A Kumar; Eliza Balazic; Derek R Muscato; Terence E Ryan; Robbert J van der Pijl; Shengyi Shen; Coen A C Ottenheijm; Leonardo F Ferreira
Journal:  J Appl Physiol (1985)       Date:  2021-11-18

3.  Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences.

Authors:  Thanh Thanh L Nguyen; Min Wang; Duan Liu; Seethalakshmi Iyer; Hilda Mariana Gonzalez Bonilla; Nancy Acker; Vishakantha Murthy; Sanskriti Shrivastava; Viral Desai; John C Burnett; Margaret Redfield; Kent R Bailey; Richard M Weinshilboum; Naveen L Pereira
Journal:  Circ Heart Fail       Date:  2022-06-03       Impact factor: 10.447

4.  Cardiac unloading by LVAD support differentially influences components of the cGMP-PKG signaling pathway in ischemic and dilated cardiomyopathy.

Authors:  Sven Persoon; Michael Paulus; Stephan Hirt; Carsten Jungbauer; Alexander Dietl; Andreas Luchner; Christof Schmid; Lars S Maier; Christoph Birner
Journal:  Heart Vessels       Date:  2018-03-15       Impact factor: 2.037

5.  The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction.

Authors:  Agata Bielecka-Dabrowa; Agata Sakowicz; Tadeusz Pietrucha; Małgorzata Misztal; Piotr Chruściel; Jacek Rysz; Maciej Banach
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

6.  Homozygous truncating mutation in NRAP gene identified by whole exome sequencing in a patient with dilated cardiomyopathy.

Authors:  Grażyna T Truszkowska; Zofia T Bilińska; Angelika Muchowicz; Agnieszka Pollak; Anna Biernacka; Katarzyna Kozar-Kamińska; Piotr Stawiński; Piotr Gasperowicz; Joanna Kosińska; Tomasz Zieliński; Rafał Płoski
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

7.  Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.

Authors:  Grazia Esposito; Donato Cappetta; Rosa Russo; Alessia Rivellino; Loreta Pia Ciuffreda; Fiorentina Roviezzo; Elena Piegari; Liberato Berrino; Francesco Rossi; Antonella De Angelis; Konrad Urbanek
Journal:  Br J Pharmacol       Date:  2017-03-21       Impact factor: 8.739

Review 8.  Role of PI3K/Akt signaling pathway in cardiac fibrosis.

Authors:  Wuming Qin; Linghui Cao; Isaac Yaw Massey
Journal:  Mol Cell Biochem       Date:  2021-07-10       Impact factor: 3.396

9.  Gene-gene Interaction Analyses for Atrial Fibrillation.

Authors:  Honghuang Lin; Martina Mueller-Nurasyid; Albert V Smith; Dan E Arking; John Barnard; Traci M Bartz; Kathryn L Lunetta; Kurt Lohman; Marcus E Kleber; Steven A Lubitz; Bastiaan Geelhoed; Stella Trompet; Maartje N Niemeijer; Tim Kacprowski; Daniel I Chasman; Derek Klarin; Moritz F Sinner; Melanie Waldenberger; Thomas Meitinger; Tamara B Harris; Lenore J Launer; Elsayed Z Soliman; Lin Y Chen; Jonathan D Smith; David R Van Wagoner; Jerome I Rotter; Bruce M Psaty; Zhijun Xie; Audrey E Hendricks; Jingzhong Ding; Graciela E Delgado; Niek Verweij; Pim van der Harst; Peter W Macfarlane; Ian Ford; Albert Hofman; André Uitterlinden; Jan Heeringa; Oscar H Franco; Jan A Kors; Stefan Weiss; Henry Völzke; Lynda M Rose; Pradeep Natarajan; Sekar Kathiresan; Stefan Kääb; Vilmundur Gudnason; Alvaro Alonso; Mina K Chung; Susan R Heckbert; Emelia J Benjamin; Yongmei Liu; Winfried März; Michiel Rienstra; J Wouter Jukema; Bruno H Stricker; Marcus Dörr; Christine M Albert; Patrick T Ellinor
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

10.  Circulating microRNA signature for the diagnosis of childhood dilated cardiomyopathy.

Authors:  Meng Jiao; Hong-Zhao You; Xin-Ying Yang; Hui Yuan; Yu-Lin Li; Wen-Xian Liu; Mei Jin; Jie Du
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.